drugset / Trial / NCT00058994

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

NCT00058994

Phase 3 Completed Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.

Timeline

Start
2003-03
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Anecortave Acetate Small molecule